
Opinions
James Hodgins
VSM MedTech Ltd.
VSM-T
DON'T BUY
Apr 21, 2014
$0.050
Stock price when the opinion was issued
biotechnology
pharmaceutical
It's the ideal tool to help you make quicker, more informed decisions for
managing and tracking your investments.
Likes this. Core business is selling broadcast equipment to cable and telcos. Have done a great job of creating shareholder value by selling off non-core assets such as wireless spectrum and real estate in Saskatchewan. Thinks they are kind of getting to the end of the line and he has sold his position.